CD8A and myeloid sarcoma: Partially aligned with these findings, co-expression of CD4 and CD8 was observed in 54% (±20%) and 46% (±17%) of CD20+ T cells in the study by Konen et al., including 53 relapsing MS patients, where T cells represented 13% (±6%) of the CD20+ lymphocytes [18].